ArticleThe Eurasian journal of medicine2026
From MASLD to MELD 3.0: Integrating the Spectrum of Liver Disease Risk Stratification into Primary Care.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2023, key advancements in liver disease were introduced into practice. Metabolic dysfunction-associated steatotic liver disease (MASLD) replaces nonalcoholic fatty liver disease (NAFLD). Model for end-stage liver disease (MELD) 3.0 replaced MELD-sodium. The prevalence of MASLD among adults is approximately 38%, and it is anticipated to rise by more than 55% by 2040. The economic burden in the USA related to MASLD exceeds $100 billion. If unrecognized, 20%-30% of adults with MASLD advance to MASH, cirrhosis of the liver, and may develop hepatocellular carcinoma. In the last 30 years, deaths related to cirrhosis have increased. As clinical approaches to screening are enhanced, the primary care physicians need to be indoctrinated. By recognizing risk factors, primary care providers can reduce the national disease burden and expedite interventions to improve patient outcomes. This manuscript aims to increase awareness of the availability of evolving knowledge necessary to minimize gatekeeping in the liver disease care path. Cite this article as: Kalluru PKR, Onteddu N, Onteddu LPR, et al. From MASLD to MELD 3.0: integrating the spectrum of liver disease risk stratification into primary care. Eurasian J Med. 2026, 58(2), 1254, doi: 10.5152/eurasianjmed.2026.251254.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.